|
Subset of SSc | Limited ( = 178) | (sclero. versus acro.) |
Diffuse ( = 56) | (limited versus diffuse) | Sclerodactyly ( = 149) | Acrosclerosis ( = 29) |
| Females, (%) | 142 (95,3) | 25 (86,2) | 0,06 | 49 (87,5) | 0,13 | Age at diagnosis, years, mean (SD) | 59,8 (15,2) | 54,9 (16,2) | 0,14 | 53 (18,3) | 0,038 | Duration of Raynaud’s prior to diagnosis, years, mean (SD) | 9,2 (3,4) | 5,5 (1) | 0,018 | 1,9 (0,8) | 0,008 | Anti-Scl-70, (%) | 9 (6,4) | 11 (39,3) | <0,001 | 18 (43,9) | <0,001 | Anticentromere, (%) | 116 (82,3) | 5 (17,9) | <0,001 | 2 (4,8) | <0,001 | Nucleolar ANA, (%) | 8 (5,7) | 1 (3,6) | 0,54 | 9 (20,9) | 0,001 | Upper GI involvement, % | 65,9 | 81,3 | 0,22 | 64,3 | 0,45 | Interstitial lung disease, % | 17,1 | 50 | <0,001 | 65,3 | <0,001 | Pulmonary hypertension + interstitial lung disease, % | 5,5 | 0 | 0,34 | 15,4 | 0,03 | Isolated pulmonary hypertension, % | 9,1 | 4,8 | 0,45 | 2,6 | 0,39 | Cardiac ultrasound abnormalities (aside from PHT), % | 5,7 | 4,5 | 0,65 | 10 | 0,26 | Digital ulcers, % | 26,9 | 34,5 | 0,44 | 32,1 | 0,86 | Renal crisis, | 0 | 0 | | 1 | | Follow-up, patient/years-years (SD) | 462 (3,1) | 81,2 (3,1) | | 144,8 (3,6) | | Being followed presently, (%) | 88 (59,5) | 15 (51,7) | | 26 (46,4) | | Deaths during follow-up, at our institution, | 11 | 2 | | 4 | |
|
|